<p>平台整合三種研究方式，針對胰腺癌腫瘤生物學的電氣特性</p>
<p>, /PRNewswire/ -- <strong>(TSXV: PAIN) —</strong> Vector Science &amp; Therapeutics（“公司”）今天宣佈提交了一項臨時專利申請，涵蓋一種新型基於導管的平台，旨在進行腫瘤內藥物遞送研究，初步科學重點為胰腺癌。該申請啓動了一項前臨牀研究計劃，探索在科學依據充分且未滿足需求仍然顯著的疾病中整合三種遞送和激活方式。</p>
<p>胰腺癌是腫瘤學中研究最為深入且持續存在的未滿足需求之一。約 80% 的患者在局部晚期或轉移期被診斷（國家癌症研究所/NCI），此時手術不可行。儘管有可用的全身治療方案，但該人羣的五年生存率仍低於 5%（NCI），文獻顯示對局部遞送策略的持續科學興趣，作為全身方法的補充或替代。Vector 的臨時專利描述了一種旨在推動該研究領域的平台架構。</p>
<p>該平台整合了三種研究方式：腫瘤內細胞分化劑的遞送、基於腫瘤組織差異導電性的電消融，以及電引導化療激活。</p>
<p><em>&#34;該平台中的三種方式都有現有文獻作為基礎。整合是新穎的。我們現在的工作是建立前臨牀證據，以確定這種整合是否能實現科學所建議的可能性。&#34;</em></p>
<p><strong>— Tom Bachinski，Vector Science &amp; Therapeutics 首席技術官</strong></p>
<p>臨時專利申請的提交確立並保護了知識產權地位，前臨牀工作開始。公司的直接重點是原理驗證：生成評估可行性、完善系統架構和支持未來監管及臨牀合作所需的基礎數據。目前尚未為該特定平台生成或發佈任何前臨牀或臨牀數據。</p>
<p><strong>關於 Vector Science &amp; Therapeutics</strong> Vector Science &amp; Therapeutics, Inc. 總部位於威斯康星州梅奎恩，開發新型生物機械設備和主動局部藥物遞送平台，以便為臨牀醫生提供在精確性至關重要且全身風險不可接受的情況下的定點干預。公司的股票在多倫多創業交易所上市，代碼為 PAIN。欲瞭解更多信息，請訪問 www.vectorscience.co。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含前瞻性聲明，包括關於公司對產品的直接關注以及所描述技術的潛力的聲明。這些聲明涉及已知和未知的風險和不確定性。臨時專利申請已提交，但尚未獲得批准。無法保證臨牀或監管里程碑將在任何特定時間表上實現，或根本無法實現。前瞻性聲明本質上是不確定的，實際表現可能受到許多重要因素、假設和期望的影響，其中許多超出了公司的控制，包括對公司的期望和假設。讀者應謹慎對待在準備任何前瞻性聲明時使用的假設可能會被證明是錯誤的。事件或情況可能導致實際結果與預測結果存在重大差異，原因是許多已知和未知的風險、不確定性和其他因素，其中許多超出了公司的控制。讀者還應謹慎對待任何前瞻性聲明，不應過度依賴這些信息，因為儘管公司管理層在準備時認為這些信息合理，但可能會被證明是錯誤的，實際結果可能與預期存在重大差異。本聲明中的信息截至本日期，Vector Science &amp; Therapeutics 不承擔更新前瞻性聲明的義務，除非法律要求。</p>
<p>多倫多創業交易所及其監管服務提供商（根據多倫多創業交易所政策中的定義）對本聲明的充分性或準確性不承擔責任。</p>
<p>來源：Vector Sciences &amp; Therapeutics</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz"/></p>

VTVT

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Vector Science & Therapeutics 已提交了一項臨時專利，旨在開發一種新型微針導管平台，專注於腫瘤內藥物遞送，初步針對胰腺癌。該平台整合了三種模式：腫瘤內細胞分化劑遞送、電消融和電引導化療激活。此次專利申請標誌着一項前臨牀研究計劃的開始，旨在驗證該技術的可行性並支持未來的監管合作。該公司旨在生成基礎數據，以優化系統架構，儘管尚未發佈任何前臨牀或臨牀數據</p>

<p>Platform Integrates Three Research Modalities Targeting the Electrical Properties of Tumor Biology in Pancreatic Cancer</p>
<div class="lb-trans"><p>平台整合三種研究方式，針對胰腺癌腫瘤生物學的電氣特性</p>
</div><p>, /PRNewswire/ -- <strong>(TSXV: PAIN) —</strong> Vector Science &amp; Therapeutics (the &#34;Company&#34;) today announced the filing of a provisional patent application covering a novel catheter-based platform designed for intratumoral drug delivery research, with an initial scientific focus on pancreatic cancer. The filing initiates a preclinical research program exploring the integration of three delivery and activation modalities in a disease where the scientific rationale for localized, targeted intervention is well established and the unmet need remains significant.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- <strong>(TSXV: PAIN) —</strong> Vector Science &amp; Therapeutics（“公司”）今天宣佈提交了一項臨時專利申請，涵蓋一種新型基於導管的平台，旨在進行腫瘤內藥物遞送研究，初步科學重點為胰腺癌。該申請啓動了一項前臨牀研究計劃，探索在科學依據充分且未滿足需求仍然顯著的疾病中整合三種遞送和激活方式。</p>
</div><p>Pancreatic cancer represents one of oncology's most studied and persistent unmet needs. Approximately 80% of patients are diagnosed at a locally advanced or metastatic stage (National Cancer Institute/NCI), where surgery is not feasible. Despite available systemic regimens, five-year survival rates remain below 5% for this population (NCI), and the literature reflects sustained scientific interest in localized delivery strategies as a complement to or alternative to systemic approaches. Vector's provisional patent describes a platform architecture intended to advance that area of research.</p>
<div class="lb-trans"><p>胰腺癌是腫瘤學中研究最為深入且持續存在的未滿足需求之一。約 80% 的患者在局部晚期或轉移期被診斷（國家癌症研究所/NCI），此時手術不可行。儘管有可用的全身治療方案，但該人羣的五年生存率仍低於 5%（NCI），文獻顯示對局部遞送策略的持續科學興趣，作為全身方法的補充或替代。Vector 的臨時專利描述了一種旨在推動該研究領域的平台架構。</p>
</div><p>The platform integrates three research modalities: intratumoral delivery of cell differentiation agents, electrical ablation based on the differential conductivity of tumor tissue, and electrically-guided chemotherapy activation.</p>
<div class="lb-trans"><p>該平台整合了三種研究方式：腫瘤內細胞分化劑的遞送、基於腫瘤組織差異導電性的電消融，以及電引導化療激活。</p>
</div><p><em>&#34;Each of the three modalities in this platform has a basis in the existing literature. The integration is novel. Our work now is to build the preclinical evidence that will determine whether that integration delivers what the science suggests is possible.&#34;</em></p>
<div class="lb-trans"><p><em>&#34;該平台中的三種方式都有現有文獻作為基礎。整合是新穎的。我們現在的工作是建立前臨牀證據，以確定這種整合是否能實現科學所建議的可能性。&#34;</em></p>
</div><p><strong>— Tom Bachinski, Chief Technology Officer, Vector Science &amp; Therapeutics</strong></p>
<div class="lb-trans"><p><strong>— Tom Bachinski，Vector Science &amp; Therapeutics 首席技術官</strong></p>
</div><p>The provisional patent filing establishes and protects the intellectual property position as preclinical work begins. The Company's immediate focus is on proof-of-principle validation: generating the foundational data required to assess feasibility, refine the system architecture, and support future regulatory and clinical collaboration. No preclinical or clinical data have yet been generated or published for this specific platform.</p>
<div class="lb-trans"><p>臨時專利申請的提交確立並保護了知識產權地位，前臨牀工作開始。公司的直接重點是原理驗證：生成評估可行性、完善系統架構和支持未來監管及臨牀合作所需的基礎數據。目前尚未為該特定平台生成或發佈任何前臨牀或臨牀數據。</p>
</div><p><strong>ABOUT VECTOR SCIENCE &amp; THERAPEUTICS</strong> Vector Science &amp; Therapeutics, Inc., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares are listed on the TSX Venture Exchange under the symbol PAIN. For more information, visit www.vectorscience.co.</p>
<div class="lb-trans"><p><strong>關於 Vector Science &amp; Therapeutics</strong> Vector Science &amp; Therapeutics, Inc. 總部位於威斯康星州梅奎恩，開發新型生物機械設備和主動局部藥物遞送平台，以便為臨牀醫生提供在精確性至關重要且全身風險不可接受的情況下的定點干預。公司的股票在多倫多創業交易所上市，代碼為 PAIN。欲瞭解更多信息，請訪問 www.vectorscience.co。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements, including statements regarding the Company's immediate focus on the product, and the potential of the described technology. These statements involve known and unknown risks and uncertainties. The provisional patent application has been filed but has not been granted. No assurance can be given that clinical or regulatory milestones will be achieved on any particular timeline, or at all. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company, including expectations and assumptions concerning the Company. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by the management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The information in this release is provided as of the date hereof and Vector Science &amp; Therapeutics undertakes no obligation to update forward-looking statements except as required by applicable law.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明，包括關於公司對產品的直接關注以及所描述技術的潛力的聲明。這些聲明涉及已知和未知的風險和不確定性。臨時專利申請已提交，但尚未獲得批准。無法保證臨牀或監管里程碑將在任何特定時間表上實現，或根本無法實現。前瞻性聲明本質上是不確定的，實際表現可能受到許多重要因素、假設和期望的影響，其中許多超出了公司的控制，包括對公司的期望和假設。讀者應謹慎對待在準備任何前瞻性聲明時使用的假設可能會被證明是錯誤的。事件或情況可能導致實際結果與預測結果存在重大差異，原因是許多已知和未知的風險、不確定性和其他因素，其中許多超出了公司的控制。讀者還應謹慎對待任何前瞻性聲明，不應過度依賴這些信息，因為儘管公司管理層在準備時認為這些信息合理，但可能會被證明是錯誤的，實際結果可能與預期存在重大差異。本聲明中的信息截至本日期，Vector Science &amp; Therapeutics 不承擔更新前瞻性聲明的義務，除非法律要求。</p>
</div><p>Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release</p>
<div class="lb-trans"><p>多倫多創業交易所及其監管服務提供商（根據多倫多創業交易所政策中的定義）對本聲明的充分性或準確性不承擔責任。</p>
</div><p>SOURCE Vector Sciences &amp; Therapeutics</p>
<div class="lb-trans"><p>來源：Vector Sciences &amp; Therapeutics</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTAxJk5ld3NJdGVtSWQ9TEE0OTAxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDEwOTI2UFJfTkVXU19VU1BSX19fX19MQTQ5MDEz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA49013&amp;Transmission_Id=202605010926PR_NEWS_USPR_____LA49013&amp;DateId=20260501"/></p>

09:26 ETVector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

prnewswire

vTv Therap

09:26 ETVector Science & Therapeutics 為一種用於腫瘤內藥物輸送的新型微針導管平台申請了臨時專利